ES75
TEAS SECTION 71 & 15 RECEIVED
07/30/2026
Back to search
Official data from USPTO
RAYBOW PHARMACEUTICAL
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
24
Latest update
07/30/2026
Trademark type
Combined
Nice classes
5, 39, 42, 44
Filing date
07/16/2019
Registration date
08/04/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/04/2020
Last transaction
07/30/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
CN
Examiner
IM, JEAN H
Law office
L10
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized wording "RAYBOW" in green and "PHARMACEUTICAL" in grey, and the design of a rainbow in dark blue, green and light blue.
Holders and representatives
Holders
Zhejiang Raybow Pharmaceutical Co., Ltd.
Representatives
Gazal Pour-Moezzi Sheppard Mullin Richter & Hampton LLP
Technical classification
Nice Classes
Class 5Class 39Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medicalpharmaceutical and veterinary preparations and substancesfor the treatment of cancercardiovascular disordersendocrinological disordersneurological disordersdermatological disordersrespiratory disorders; as well as health care preparationspharmaceutical preparations for the treatment of cancercardiovascular disordersendocrinological disordersneurological disordersdermatological disordersrespiratory disorders; medicines for the treatment of diseases associated with the central nervous system; hypoglycemic drugs; medicines for the treatment of antiviral disorders; medicines for the treatment of tumors; cardiovascular treatment preparations; nonsteroidal anti-inflammatory drugs; anti-infectives; chemical preparations for veterinary or pharmaceutical purposesnamely for the treatment of cancercardiovascular disordersendocrinological disordersneurological disordersdermatological disordersrespiratory disorders
Class 39
Distribution of products in the field of pharmaceuticalstransportation and delivery of health care preparations in the form of pharmaceutical productsincluding finished products and semi-finished products for veterinary and cosmetic purposes
Class 42
Pharmaceutical research for the discovery of new drugs; scientific researchin particular in the medicalbiomedicalchemicalgeneticpharmaceutical or veterinary fields; research and development of new pharmaceutical preparations for others; scientific research in the field of pharmacy
Class 44
Medical servicesveterinary services; medical consultancy in the field of healthcare and dispensing of pharmaceutical preparations and pharmaceutical consultancy in the field of healthcare and dispensing of pharmaceutical preparationsthe aforesaid services also provided via electronic networksincluding the internet
Publications
History of USPTO decisions and trademark events.
24 publications found
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
08/04/2025
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/12/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
11/25/2020
FIMP
FINAL DISPOSITION PROCESSED
11/25/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/04/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
08/04/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/19/2020
PUBO
PUBLISHED FOR OPPOSITION
05/19/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/29/2020
ALIE
ASSIGNED TO LIE
04/13/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/06/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/04/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/03/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/03/2020
RFNT
REFUSAL PROCESSED BY IB
12/20/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
11/19/2019
RFRR
REFUSAL PROCESSED BY MPU
11/19/2019
MAFR
APPLICATION FILING RECEIPT MAILED
10/29/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
10/27/2019
CNRT
NON-FINAL ACTION WRITTEN
10/26/2019
DOCK
ASSIGNED TO EXAMINER
10/25/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/25/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/24/2019
Continuous trademark protection
Get notified about every new filing that threatens RAYBOW PHARMACEUTICAL or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.